Net Net Stock Overview

Subscribe

To see hundreds more international net nets, consider subscribing

Overview

Atreca Inc
Healthcare
P/NCAV
0.34x
Ticker
BCEL
Exchange
Over The Counter
Country
United States
Close
0.08 $
Mkt Cap
3.1M $
EV
-10.4M $
NCAV Burn Rate
46.3%
Current Ratio
1.58
Debt/Equity
0.0
EV/REV
N/Ax
EV/EBIT
0.1x
EV/FCF
0.1x
Dilution
7.6% p.A
Total Net Income
-425.8M $
Cheapness
100.0%
Atreca, Inc. is a clinical-stage biopharmaceutical company. The Company is discovering and developing antibody-based therapeutics to treat a range of solid tumor types. Its most advanced product candidate, ATRC-101, is a monoclonal antibody with a mechanism of action and target derived from an antibody identified using its discovery platform. ATRC-101 reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal and breast cancer samples from multiple patients. It commenced clinical development of ATRC-101 with a Phase Ib clinical trial evaluating ATRC-101 as a monotherapy in patients with select solid tumors and opens a new cohort to evaluate ATRC-101 in combination with pembrolizumab, a PD-1 checkpoint inhibitor. It is also advancing additional product candidates using its discovery platform. Its oncology programs include APN-497444, an ADC against a tumor glycan target, and APN-346958, a CD3 bispecific T-cell engager against an RNA-binding protein target.

Profitability

positive values --- Average negative values

Margins

--- Average

Valuation

positive values --- Average negative values

Dilution

--- Average